BiotechTube

LY2584702 + Erlotinib + Everolimus

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastases, Neoplasm

Conditions

Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors

Trial Timeline

Mar 1, 2010 → Jun 1, 2011

NCT ID
NCT01115803

About LY2584702 + Erlotinib + Everolimus

LY2584702 + Erlotinib + Everolimus is a phase 1 stage product being developed by Eli Lilly for Metastases, Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT01115803. Target conditions include Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01115803Phase 1Terminated

Competing Products

20 competing products in Metastases, Neoplasm

See all competitors
ProductCompanyStageHype Score
LY2780301Eli LillyPhase 1
33
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Patritumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
77
Leuprorelin AcetateAstellas PharmaPhase 3
77
Pembrolizumab + LenvatinibEisaiPhase 2
52
ALIMTA + folic acid + multi-vitaminsEli LillyPhase 1
33
MerestinibEli LillyPhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
temozolomideMerckPhase 2
52
VorinostatMerckPhase 1
33
PembrolizumabMerckPhase 2
52
EMD 525797MerckPhase 1
33
TemozolomideMerckPhase 2
52
cabazitaxel + lapatinibNovartisPhase 2
52
BKM120 + capecitabine + TrastuzumabNovartisPhase 2
52
Zoledronic acidNovartisPhase 3
77
zoledronic acidNovartisPhase 1
33
capecitabine + lapatinib + trastuzumabNovartisPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85